Cell Adhesion Molecules: Potential Therapeutic & Diagnostic Implications

Overview

Journal Mol Biotechnol

Publisher Springer

Specialties Biotechnology
Molecular Biology

Date 2007 Dec 21

PMID 18095189

Citations 37

Authors

Shaker A Mousa

Affiliations

Soon will be listed here.

Abstract

The role of cell adhesion molecules (CAM) and extracellular matrix proteins (ECM) in various pathological processes including angiogenesis, thrombosis, apoptosis, cell migration & proliferation are well documented. These processes can lead to both acute and chronic disease states such as ocular diseases, metastasis, unstable angina, myocardial infarction, stroke, osteoporosis, a wide range of inflammatory diseases, vascular remodeling, and neurodegenerative disorders. A key success in this field is evident from the potential role of the platelet GPIIb/IIIa integrin in the prevention and diagnosis of various thromboembolic disorders. Additionally, the use of soluble adhesion molecules as potential diagnostic markers for acute and chronic leukocyte, platelet, and endothelial cellular insult are increasingly utilized. The development of various therapeutic and diagnostic candidates based on the key role of CAM, with special emphasis on integrins in various diseases as well as the structure-function aspects of cell adhesion and signaling of the different CAM and ECM are highlighted.

Citing Articles

Enhanced interaction between genome-edited mesenchymal stem cells and platelets improves wound healing in mice.

Li D, Li Y, Lv D, Deng T, Zeng X, You L J Tissue Eng. 2024; 15:20417314241268917.

PMID: 39329066 PMC: 11425747. DOI: 10.1177/20417314241268917.

Perilla oil and α-linolenic acid ameliorated thrombosis in rats induced by collagen and epinephrine.

Kim J, Lee S, Son M, Zhou Y, Qiu S, Park H Food Sci Biotechnol. 2023; 32(7):997-1003.

PMID: 37123064 PMC: 10130252. DOI: 10.1007/s10068-022-01241-6.

Levels of adhesion molecules and clinical outcomes in patients with ischemic stroke after mechanical thrombectomy.

Zhang X, Zhou F, Wang W, E Y, Chen S, Cao H Front Neurol. 2022; 13:1024162.

PMID: 36247764 PMC: 9556902. DOI: 10.3389/fneur.2022.1024162.

The progress of research on histone methylation in ischemic stroke pathogenesis.

Su Y, Zhang L, Zhou Y, Ding L, Li L, Wang Z J Physiol Biochem. 2021; 78(1):1-8.

PMID: 34472033 DOI: 10.1007/s13105-021-00841-w.

The Impact of Spaceflight and Simulated Microgravity on Cell Adhesion.

Lin X, Zhang K, Wei D, Tian Y, Gao Y, Chen Z Int J Mol Sci. 2020; 21(9).

PMID: 32344794 PMC: 7246714. DOI: 10.3390/ijms21093031.

References

Quinn M, Fitzgerald D . Long-term administration of glycoprotein IIb/IIIa antagonists. Am Heart J. 1998; 135(5 Pt 2 Su):S113-8. DOI: 10.1016/s0002-8703(98)70239-x. View

Elices M, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler M . VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell. 1990; 60(4):577-84. DOI: 10.1016/0092-8674(90)90661-w. View

Brooks P, Montgomery A, Rosenfeld M, Reisfeld R, Hu T, Klier G . Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994; 79(7):1157-64. DOI: 10.1016/0092-8674(94)90007-8. View

Cerf-Bensussan N, Jarry A, Brousse N, Griscelli C . A monoclonal antibody (HML-1) defining a novel membrane molecule present on human intestinal lymphocytes. Eur J Immunol. 1987; 17(9):1279-85. DOI: 10.1002/eji.1830170910. View

Cannella B, Raine C . The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann Neurol. 1995; 37(4):424-35. DOI: 10.1002/ana.410370404. View

Haug C, Colvin R, Delmonico F, Auchincloss Jr H, Tolkoff-Rubin N, Preffer F . A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation. 1993; 55(4):766-72; discussion 772-3. DOI: 10.1097/00007890-199304000-00016. View

Tcheng J, ELLIS S, GEORGE B, Kereiakes D, Kleiman N, Talley J . Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 1994; 90(4):1757-64. DOI: 10.1161/01.cir.90.4.1757. View

Lasky L, Singer M, Dowbenko D, Imai Y, Henzel W, Grimley C . An endothelial ligand for L-selectin is a novel mucin-like molecule. Cell. 1992; 69(6):927-38. DOI: 10.1016/0092-8674(92)90612-g. View

Mulligan M, Paulson J, De Frees S, Zheng Z, Lowe J, Ward P . Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature. 1993; 364(6433):149-51. DOI: 10.1038/364149a0. View

10.

Mousa S, Bozarth J, Edwards S, Carroll T, Barrett J . Novel technetium-99m-labeled platelet GPIIb/IIIa receptor antagonists as potential imaging agents for venous and arterial thrombosis. Coron Artery Dis. 1998; 9(2-3):131-41. View

11.

Mousa S, Bozarth J, Forsythe M, Jackson S, Leamy A, Diemer M . Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation. 1994; 89(1):3-12. DOI: 10.1161/01.cir.89.1.3. View

12.

Liaw L, Skinner M, Raines E, Ross R, Cheresh D, Schwartz S . The adhesive and migratory effects of osteopontin are mediated via distinct cell surface integrins. Role of alpha v beta 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest. 1995; 95(2):713-24. PMC: 295539. DOI: 10.1172/JCI117718. View

13.

Weyrich A, Ma X, Lefer D, Albertine K, Lefer A . In vivo neutralization of P-selectin protects feline heart and endothelium in myocardial ischemia and reperfusion injury. J Clin Invest. 1993; 91(6):2620-9. PMC: 443326. DOI: 10.1172/JCI116501. View

14.

Simpson P, Todd 3rd R, Mickelson J, Fantone J, Gallagher K, Lee K . Sustained limitation of myocardial reperfusion injury by a monoclonal antibody that alters leukocyte function. Circulation. 1990; 81(1):226-37. DOI: 10.1161/01.cir.81.1.226. View

15.

Brooks P, Clark R, Cheresh D . Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science. 1994; 264(5158):569-71. DOI: 10.1126/science.7512751. View

16.

Yednock T, Cannon C, Fritz L, Sanchez-Madrid F, Steinman L, Karin N . Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992; 356(6364):63-6. DOI: 10.1038/356063a0. View

17.

Muller T, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J . Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997; 96(4):1130-8. DOI: 10.1161/01.cir.96.4.1130. View

18.

Vorchheimer D, Fuster V . Oral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety. Circulation. 1998; 97(4):312-4. DOI: 10.1161/01.cir.97.4.312. View

19.

Peerlinck K, De Lepeleire I, Goldberg M, Farrell D, Barrett J, Hand E . MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man. Circulation. 1993; 88(4 Pt 1):1512-7. DOI: 10.1161/01.cir.88.4.1512. View

20.

Mousa S, Bozarth J, Forsythe M, Lorelli W, Thoolen M, Ramachandran N . Antiplatelet efficacy and specificity of DMP728, a novel platelet GPIIb/IIIa receptor antagonist. Cardiology. 1993; 83(5-6):374-82. DOI: 10.1159/000175994. View